Free Trial
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free RNAC Stock Alerts

Cartesian Therapeutics (RNAC) Financials

Cartesian Therapeutics logo
$9.51 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$9.58 +0.07 (+0.74%)
As of 06/12/2026 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Cartesian Therapeutics

Annual Income Statements for Cartesian Therapeutics

This table shows Cartesian Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 35 -220 -77
Consolidated Net Income / (Loss)		 35 -220 -77
Net Income / (Loss) Continuing Operations		 36 -220 -77
Total Pre-Tax Income 		35 -239 -77
Total Operating Income		 15 -86 -44
Total Gross Profit		 111 26 39
Total Revenue		 111 26 39
Operating Revenue		 111 26 39
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 96 112 83
Selling, General & Admin Expense		 24 40 30
Research & Development Expense		 72 71 45
Impairment Charge		 - 0.71 7.58
Total Other Income / (Expense), net		 20 -152 -33
Interest Expense		 3.03 2.83 0.00
Interest & Investment Income		 2.07 4.96 7.39
Other Income / (Expense), net		 21 -154 -41
Income Tax Expense		 -0.61 -19 0.29
Basic Earnings per Share		 $0.24 ($49.76) ($4.48)
Weighted Average Basic Shares Outstanding		 144.76M 5.17M 17.28M
Diluted Earnings per Share		 $0.10 ($49.76) ($4.49)
Weighted Average Diluted Shares Outstanding		 145.87M 5.17M 17.36M
Weighted Average Basic & Diluted Shares Outstanding		 153.32M 161.95M 25.91M

Quarterly Income Statements for Cartesian Therapeutics

This table shows Cartesian Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -7.89 5.89 -22 -11 -9.00 -178 -57 9.63 -24 -6.05
Consolidated Net Income / (Loss)		 -7.89 5.89 -22 -11 -9.00 -178 -57 14 -24 -10
Net Income / (Loss) Continuing Operations		 -7.89 1.58 -18 -18 -13 -172 -57 15 -24 -12
Total Pre-Tax Income 		-8.21 1.11 -18 -18 -13 -190 -57 15 -24 -10
Total Operating Income		 -1.60 -8.50 -18 -19 -13 -36 -13 14 -18 -27
Total Gross Profit		 21 17 5.94 5.25 6.55 8.27 5.84 33 0.39 -0.76
Total Revenue		 21 17 5.94 5.25 6.55 8.27 5.84 33 0.39 -0.76
Operating Revenue		 21 17 5.94 5.25 6.55 8.27 5.84 33 0.39 -0.76
Total Operating Expenses		 22 25 24 24 20 45 19 20 18 26
Selling, General & Admin Expense		 5.77 6.32 5.70 6.11 6.61 22 9.45 7.03 6.56 7.09
Research & Development Expense		 17 19 19 18 13 22 9.74 13 11 11
Total Other Income / (Expense), net		 -6.62 9.28 0.54 0.67 0.02 -154 -44 1.20 -6.86 16
Interest & Investment Income		 0.71 1.14 1.33 1.39 1.30 0.94 1.16 1.20 2.57 2.45
Basic Earnings per Share		 ($0.05) $0.04 ($4.24) ($2.23) ($1.74) ($34.36) ($10.50) $0.58 ($1.13) ($0.35)
Weighted Average Basic Shares Outstanding		 152.85M 144.76M 5.11M 5.11M 5.16M 5.17M 5.41M 16.72M 21.47M 17.28M
Diluted Earnings per Share		 ($0.05) $0.04 ($4.24) ($2.23) ($1.74) ($34.36) ($10.50) $0.54 ($1.13) ($0.35)
Weighted Average Diluted Shares Outstanding		 152.85M 145.87M 5.11M 5.11M 5.16M 5.17M 5.41M 17.79M 21.47M 17.36M
Basic & Diluted Earnings per Share		 - $0.04 - - - ($34.36) - - - ($0.35)
Weighted Average Basic & Diluted Shares Outstanding		 153.03M 153.32M 153.43M 153.43M 155.20M 161.95M 17.80M 21.38M 25.41M 25.91M

Annual Cash Flow Statements for Cartesian Therapeutics

This table details how cash moves in and out of Cartesian Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -7.40 -30 136
Net Cash From Operating Activities		 -32 -51 -24
Net Cash From Continuing Operating Activities		 -32 -51 -24
Net Income / (Loss) Continuing Operations		 35 -220 -77
Consolidated Net Income / (Loss)		 35 -220 -77
Depreciation Expense		 1.29 0.84 1.15
Amortization Expense		 -0.38 -0.08 0.00
Non-Cash Adjustments To Reconcile Net Income		 -11 182 61
Changes in Operating Assets and Liabilities, net		 -57 -14 -8.49
Net Cash From Investing Activities		 -15 35 -8.74
Net Cash From Continuing Investing Activities		 -15 35 -8.74
Purchase of Property, Plant & Equipment		 -1.20 -0.21 -9.09
Acquisitions		 0.00 6.56 0.00
Sale of Property, Plant & Equipment		 - 0.00 0.35
Sale and/or Maturity of Investments		 20 28 0.00
Net Cash From Financing Activities		 39 -13 168
Net Cash From Continuing Financing Activities		 39 -13 168
Repayment of Debt		 -0.11 -27 0.00
Repurchase of Common Equity		 - 0.00 -0.07
Issuance of Preferred Equity		 0.00 20 40
Issuance of Common Equity		 39 0.23 124
Other Financing Activities, net		 0.16 -6.17 4.06
Effect of Exchange Rate Changes		 0.02 -0.05 -0.02
Cash Interest Paid		 2.25 1.85 0.00

Quarterly Cash Flow Statements for Cartesian Therapeutics

This table details how cash moves in and out of Cartesian Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -25 -6.41 19 -13 -34 -2.69 27 -16 132 -6.59
Net Cash From Operating Activities		 4.35 -12 -8.77 -9.90 -9.22 -23 -16 -14 14 -7.00
Net Cash From Continuing Operating Activities		 4.35 -12 -8.77 -9.90 -9.22 -23 -16 -14 14 -7.00
Net Income / (Loss) Continuing Operations		 -7.89 5.89 -22 -11 -9.00 -178 -57 14 -24 -10
Consolidated Net Income / (Loss)		 -7.89 5.89 -22 -11 -9.00 -178 -57 14 -24 -10
Depreciation Expense		 0.35 0.24 0.21 0.18 0.19 0.27 0.18 0.20 0.29 0.49
Non-Cash Adjustments To Reconcile Net Income		 9.34 -13 8.49 -1.21 -1.19 176 48 2.50 14 -3.39
Changes in Operating Assets and Liabilities, net		 2.35 -3.88 4.28 2.53 0.79 -22 -6.98 -31 23 6.15
Net Cash From Investing Activities		 -30 5.49 28 -0.01 - 6.50 -0.60 -1.59 -6.20 -0.35
Net Cash From Continuing Investing Activities		 -30 5.63 28 -0.01 - 6.50 -0.60 -1.59 -6.20 -0.35
Purchase of Property, Plant & Equipment		 -0.58 -0.07 -0.13 -0.01 - -0.06 -0.60 -1.59 -6.20 -0.71
Net Cash From Financing Activities		 0.61 - 0.15 -2.59 -25 14 43 0.12 124 0.78
Net Cash From Continuing Financing Activities		 0.61 - 0.15 -2.59 -25 14 43 0.12 124 0.78
Other Financing Activities, net		 0.14 - 0.00 - - -6.17 3.03 0.12 0.06 0.85
Effect of Exchange Rate Changes		 - - -0.02 -0.03 -0.02 0.02 -0.01 0.01 -0.02 -0.02

Annual Balance Sheets for Cartesian Therapeutics

This table presents Cartesian Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 166 305 435
Total Current Assets		 148 91 217
Cash & Equivalents		 106 77 213
Accounts Receivable		 9.76 5.87 0.87
Prepaid Expenses		 3.78 4.97 3.14
Other Current Assets		 - 2.98 0.00
Plant, Property, & Equipment, net		 2.79 2.11 9.91
Total Noncurrent Assets		 15 212 208
Long-Term Investments		 2.00 2.00 2.00
Goodwill		 0.00 48 48
Intangible Assets		 0.00 151 151
Other Noncurrent Operating Assets		 12 10 6.05
Other Noncurrent Nonoperating Assets		 1.31 1.38 1.67
Total Liabilities & Shareholders' Equity		 166 305 435
Total Liabilities		 72 445 442
Total Current Liabilities		 25 68 23
Accounts Payable		 0.32 3.15 0.29
Accrued Expenses		 14 16 12
Current Deferred Revenue		 0.59 2.31 0.00
Other Current Liabilities		 1.61 47 11
Total Noncurrent Liabilities		 47 380 419
Noncurrent Deferred Revenue		 0.00 3.54 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 0.00 16 16
Other Noncurrent Operating Liabilities		 29 361 403
Commitments & Contingencies		 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 297 0.00
Total Equity & Noncontrolling Interests		 94 -440 -6.80
Total Preferred & Common Equity		 94 -440 -6.80
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 94 -440 -6.80
Common Stock		 493 179 690
Retained Earnings		 -395 -615 -692
Accumulated Other Comprehensive Income / (Loss)		 -4.56 -4.60 -4.62

Quarterly Balance Sheets for Cartesian Therapeutics

This table presents Cartesian Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 178 156 140 106 325 348 455
Total Current Assets		 160 138 123 90 111 125 229
Cash & Equivalents		 113 126 112 80 103 87 219
Accounts Receivable		 6.93 6.84 5.39 4.90 2.01 32 4.83
Prepaid Expenses		 6.31 3.79 4.26 3.49 3.32 2.04 4.13
Other Current Assets		 - 1.84 1.06 1.88 2.37 3.47 0.98
Plant, Property, & Equipment, net		 2.90 2.77 2.59 2.42 2.40 6.67 10
Total Noncurrent Assets		 16 15 14 14 212 216 216
Long-Term Investments		 2.00 2.00 2.00 2.00 2.00 2.00 2.00
Goodwill		 - - - - 48 48 48
Intangible Assets		 - - - - 151 151 151
Other Noncurrent Operating Assets		 12 11 11 10 9.56 14 14
Other Noncurrent Nonoperating Assets		 1.60 1.31 1.38 1.38 1.38 1.67 1.67
Total Liabilities & Shareholders' Equity		 178 156 140 106 325 348 455
Total Liabilities		 93 81 74 46 442 449 455
Total Current Liabilities		 24 27 29 20 37 26 21
Accounts Payable		 0.21 1.06 0.27 0.38 2.52 2.86 0.52
Accrued Expenses		 12 9.35 13 14 9.52 11 9.45
Current Deferred Revenue		 3.82 4.23 4.23 4.14 0.41 0.00 0.00
Other Current Liabilities		 1.55 1.67 1.73 1.79 24 12 11
Total Noncurrent Liabilities		 70 55 45 26 405 423 433
Noncurrent Deferred Revenue		 5.44 5.52 4.86 3.98 0.00 0.00 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - 16 16 16
Other Noncurrent Operating Liabilities		 44 33 26 22 390 407 417
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 85 75 65 60 -117 -101 0.75
Total Preferred & Common Equity		 85 75 65 60 -117 -101 0.75
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 85 75 65 60 -117 -101 0.75
Common Stock		 490 496 498 502 559 561 687
Retained Earnings		 -401 -417 -428 -437 -671 -658 -682
Accumulated Other Comprehensive Income / (Loss)		 -4.53 -4.57 -4.60 -4.62 -4.61 -4.59 -4.61

Annual Metrics And Ratios for Cartesian Therapeutics

This table displays calculated financial ratios and metrics derived from Cartesian Therapeutics' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 30.21% -76.53% 49.64%
EBITDA Growth		 905.46% -761.19% 65.27%
EBIT Growth		 610.35% -780.38% 64.91%
NOPAT Growth		 559.70% -508.93% 49.20%
Net Income Growth		 237.73% -721.02% 64.76%
EPS Growth		 145.45% -721.02% 90.98%
Operating Cash Flow Growth		 47.62% -61.74% 53.73%
Free Cash Flow Firm Growth		 4.80% 386.81% -121.52%
Invested Capital Growth		 78.60% -1,154.68% 0.24%
Revenue Q/Q Growth		 -10.61% -24.70% -18.83%
EBITDA Q/Q Growth		 -0.21% -379.77% -58.62%
EBIT Q/Q Growth		 -1.92% -385.61% -57.99%
NOPAT Q/Q Growth		 -45.44% -47.52% 17.95%
Net Income Q/Q Growth		 -15.21% -507.62% 68.38%
EPS Q/Q Growth		 -62.96% -507.62% 61.29%
Operating Cash Flow Q/Q Growth		 38.27% -28.79% 40.75%
Free Cash Flow Firm Q/Q Growth		 26.78% 353.17% -119.30%
Invested Capital Q/Q Growth		 54.35% -887.25% -0.43%
Profitability Metrics		 - - -
Gross Margin		 100.00% 100.00% 100.00%
EBITDA Margin		 32.78% -923.23% -214.25%
Operating Margin		 13.12% -332.32% -112.81%
EBIT Margin		 31.95% -926.17% -217.21%
Profit (Net Income) Margin		 31.94% -844.91% -198.97%
Tax Burden Percent		 101.75% 92.04% 100.37%
Interest Burden Percent		 98.23% 99.12% 91.26%
Effective Tax Rate		 -1.75% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 60.82% 887.63% 103.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 21.73% -102.28% -22.84%
Return on Assets (ROA)		 21.72% -93.31% -20.92%
Return on Common Equity (ROCE)		 60.82% 6,210.18% 307.07%
Return on Equity Simple (ROE_SIMPLE)		 37.71% 49.91% 1,138.25%
Net Operating Profit after Tax (NOPAT)		 15 -60 -31
NOPAT Margin		 13.35% -232.62% -78.97%
Net Nonoperating Expense Percent (NNEP)		 18.93% -165.91% -31.49%
Return On Investment Capital (ROIC_SIMPLE)		 - 13.74% 451.75%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 21.54% 155.55% 77.42%
R&D to Revenue		 65.34% 274.03% 115.91%
Operating Expenses to Revenue		 86.88% 432.32% 212.81%
Earnings before Interest and Taxes (EBIT)		 35 -241 -85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 36 -240 -83
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.84 0.00 0.00
Price to Tangible Book Value (P/TBV)		 1.84 0.00 0.00
Price to Revenue (P/Rev)		 1.56 4.11 11.70
Price to Earnings (P/E)		 4.89 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 20.46% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.57 12.50 6.18
Enterprise Value to EBITDA (EV/EBITDA)		 1.72 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 1.77 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 4.23 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 2.24 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.28 0.00 0.00
Long-Term Debt to Equity		 0.19 0.00 0.00
Financial Leverage		 -1.87 3.88 1.98
Leverage Ratio		 2.80 -9.51 -4.93
Compound Leverage Factor		 2.75 -9.43 -4.50
Debt to Total Capital		 21.87% 0.00% 0.00%
Short-Term Debt to Total Capital		 7.06% 0.00% 0.00%
Long-Term Debt to Total Capital		 14.81% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -207.11% 0.00%
Common Equity to Total Capital		 78.13% 307.11% 100.00%
Debt to EBITDA		 0.72 0.00 0.00
Net Debt to EBITDA		 -3.04 0.00 0.00
Long-Term Debt to EBITDA		 0.49 0.00 0.00
Debt to NOPAT		 1.78 0.00 0.00
Net Debt to NOPAT		 -7.46 0.00 0.00
Long-Term Debt to NOPAT		 1.20 0.00 0.00
Altman Z-Score		 0.37 -5.11 -1.63
Noncontrolling Interest Sharing Ratio		 0.00% -599.64% -197.72%
Liquidity Ratios		 - - -
Current Ratio		 5.91 1.33 9.43
Quick Ratio		 5.76 1.21 9.29
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -51 145 -31
Operating Cash Flow to CapEx		 -2,633.72% -24,835.44% -270.81%
Free Cash Flow to Firm to Interest Expense		 -16.72 51.29 0.00
Operating Cash Flow to Interest Expense		 -10.44 -18.06 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -10.83 -18.13 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.68 0.11 0.11
Accounts Receivable Turnover		 11.26 3.33 11.54
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 44.89 10.60 6.47
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 32.41 109.68 31.62
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 32.41 109.68 31.62
Capital & Investment Metrics		 - - -
Invested Capital		 -18 -224 -223
Invested Capital Turnover		 -2.19 -0.22 -0.17
Increase / (Decrease) in Invested Capital		 65 -206 0.54
Enterprise Value (EV)		 63 325 241
Market Capitalization		 173 107 455
Book Value per Share		 $0.61 ($2.84) ($0.27)
Tangible Book Value per Share		 $0.61 ($4.12) ($8.09)
Total Capital		 120 -143 -6.80
Total Debt		 26 0.00 0.00
Total Long-Term Debt		 18 0.00 0.00
Net Debt		 -110 -79 -215
Capital Expenditures (CapEx)		 1.20 0.21 8.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.07 -54 -19
Debt-free Net Working Capital (DFNWC)		 132 23 194
Net Working Capital (NWC)		 123 23 194
Net Nonoperating Expense (NNE)		 -21 159 47
Net Nonoperating Obligations (NNO)		 -112 -80 -216
Total Depreciation and Amortization (D&A)		 0.91 0.76 1.15
Debt-free, Cash-free Net Working Capital to Revenue		 -2.77% -209.16% -48.72%
Debt-free Net Working Capital to Revenue		 118.74% 86.60% 497.65%
Net Working Capital to Revenue		 111.09% 86.60% 497.65%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $7.20 ($49.80) ($4.48)
Adjusted Weighted Average Basic Shares Outstanding		 4.83M 5.17M 17.28M
Adjusted Diluted Earnings per Share		 $3.00 ($49.80) ($4.49)
Adjusted Weighted Average Diluted Shares Outstanding		 4.86M 5.17M 17.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.11M 5.40M 25.91M
Normalized Net Operating Profit after Tax (NOPAT)		 10 -60 -25
Normalized NOPAT Margin		 9.19% -230.71% -65.33%
Pre Tax Income Margin		 31.39% -917.97% -198.23%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 11.68 -85.01 0.00
NOPAT to Interest Expense		 4.88 -21.35 0.00
EBIT Less CapEx to Interest Expense		 11.28 -85.09 0.00
NOPAT Less CapEx to Interest Expense		 4.48 -21.43 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.09%

Quarterly Metrics And Ratios for Cartesian Therapeutics

This table displays calculated financial ratios and metrics derived from Cartesian Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -15.22% -43.90% -82.53% -86.63% -68.37% -50.78% -1.65% 537.17% -94.09% -109.18%
EBITDA Growth		 -2,716.61% -176.57% -160.86% -228.07% -70.31% -39,021.97% -219.79% 175.67% -107.47% 86.22%
EBIT Growth		 -494.66% -60.72% -162.63% -235.32% -60.88% -42,593.54% -218.57% 173.90% -106.66% 85.99%
NOPAT Growth		 18.79% -308.34% -219.43% -194.13% -717.07% -199.35% 27.38% 205.45% -34.52% 26.43%
Net Income Growth		 55.89% -51.85% -175.28% -232.39% -14.05% -3,114.73% -162.31% 221.51% -168.64% 94.23%
EPS Growth		 68.75% -63.64% -175.28% -232.39% -14.05% -3,114.73% -162.31% 124.22% 35.06% 98.98%
Operating Cash Flow Growth		 140.51% 62.34% 26.12% 19.36% -311.69% -96.52% -81.60% -45.99% 248.57% 69.93%
Free Cash Flow Firm Growth		 -2,857.73% -61.05% 74.41% 80.38% 73.79% 343.90% 876.25% 1,158.46% 832.95% -110.67%
Invested Capital Growth		 71.15% 78.60% 28.24% 13.29% 41.98% -1,154.68% -692.58% -641.71% -880.60% 0.24%
Revenue Q/Q Growth		 -47.27% -18.90% -64.64% -11.60% 24.80% 26.18% -29.35% 472.69% -98.84% -296.12%
EBITDA Q/Q Growth		 -152.52% 93.56% -3,644.35% -1.12% 30.15% -1,379.34% 70.03% 123.93% -291.50% 1.78%
EBIT Q/Q Growth		 -159.05% 105.53% -4,189.53% -1.38% 29.80% -1,360.02% 69.98% 123.52% -296.31% 1.02%
NOPAT Q/Q Growth		 -108.08% -659.05% -51.44% -1.40% 29.90% -178.09% 63.26% 247.23% -189.43% -52.10%
Net Income Q/Q Growth		 -191.77% 174.66% -467.61% 47.44% 20.94% -1,873.54% 68.02% 124.35% -274.78% 57.60%
EPS Q/Q Growth		 -183.33% 180.00% -467.61% 47.44% 20.94% -1,873.54% 68.02% 105.14% -309.26% 69.03%
Operating Cash Flow Q/Q Growth		 135.47% -372.20% 26.03% -12.89% 6.87% -152.70% 31.65% 9.24% 194.77% -151.14%
Free Cash Flow Firm Q/Q Growth		 -12.31% 24.09% 67.59% 28.97% -50.01% 806.33% 3.15% -3.15% 3.88% -110.29%
Invested Capital Q/Q Growth		 -30.53% 54.35% -58.28% 8.07% 12.66% -887.25% 0.01% 13.97% -15.47% -0.43%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -36.51% -2.90% -307.09% -351.29% -196.60% -2,304.91% -998.51% 41.72% -6,904.39% 0.00%
Operating Margin		 -7.72% -50.59% -309.55% -355.08% -199.44% -439.54% -228.56% 41.13% -4,541.34% 0.00%
EBIT Margin		 -39.22% 2.67% -309.23% -354.64% -199.48% -2,308.20% -1,001.64% 41.13% -6,978.29% 0.00%
Profit (Net Income) Margin		 -38.11% 35.09% -364.82% -216.94% -137.41% -2,149.26% -973.01% 41.37% -6,248.84% 0.00%
Tax Burden Percent		 96.09% 529.95% 121.44% 63.36% 69.02% 93.58% 99.11% 92.54% 98.98% 99.31%
Interest Burden Percent		 101.12% 247.66% 97.15% 96.55% 99.80% 99.51% 98.01% 108.69% 90.47% 38.62%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 126.10% 60.82% -23.11% -45.21% -49.79% 887.63% 1,207.32% 1,275.47% -801.65% 103.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -28.14% 1.82% -169.74% -105.43% -48.46% -254.91% -107.92% 9.13% -1,191.86% 0.00%
Return on Assets (ROA)		 -27.34% 23.86% -200.25% -64.49% -33.38% -237.35% -104.83% 9.19% -1,067.27% 0.00%
Return on Common Equity (ROCE)		 126.10% 60.82% -23.11% -45.21% -49.79% 6,210.18% 1,207.32% 1,275.47% -801.65% 307.07%
Return on Equity Simple (ROE_SIMPLE)		 49.14% 0.00% -20.20% -53.55% -59.94% 0.00% 218.21% 226.35% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.12 -8.50 -13 -13 -9.15 -25 -9.34 14 -12 -19
NOPAT Margin		 -5.40% -50.59% -216.68% -248.55% -139.60% -307.67% -159.99% 41.13% -3,178.94% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.63% 13.23% -8.89% 1.57% 0.14% -158.62% -45.31% 0.09% -7.77% 5.70%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 5.78% - - - 275.09%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 27.86% 37.65% 95.91% 116.31% 100.96% 266.59% 161.82% 21.01% 1,695.61% 0.00%
R&D to Revenue		 79.86% 112.93% 313.64% 338.77% 198.47% 264.36% 166.75% 37.86% 2,945.74% 0.00%
Operating Expenses to Revenue		 107.72% 150.59% 409.55% 455.08% 299.44% 539.54% 328.56% 58.87% 4,641.34% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.12 0.45 -18 -19 -13 -191 -58 14 -27 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.56 -0.49 -18 -18 -13 -191 -58 14 -27 -26
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.95 1.84 2.86 2.63 2.70 0.00 0.00 0.00 458.36 0.00
Price to Tangible Book Value (P/TBV)		 2.95 1.84 2.86 2.63 2.70 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.02 1.56 2.58 3.53 4.71 4.11 4.06 8.88 7.19 11.70
Price to Earnings (P/E)		 6.00 4.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 16.66% 20.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1.03 0.57 1.35 1.68 2.35 12.50 0.00 7.24 2.58 6.18
Enterprise Value to EBITDA (EV/EBITDA)		 3.52 1.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 3.55 1.77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 4.72 4.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 2.24 0.00 2.96 0.76 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.31 0.28 0.35 0.37 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.24 0.19 0.22 0.21 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -3.64 -1.87 -1.52 -1.36 -1.42 3.88 4.96 5.06 -5.01 1.98
Leverage Ratio		 5.22 2.80 2.31 2.11 1.96 -9.51 -11.39 -13.53 9.19 -4.93
Compound Leverage Factor		 5.28 6.93 2.25 2.04 1.95 -9.47 -11.16 -14.71 8.31 -1.90
Debt to Total Capital		 23.51% 21.87% 26.18% 26.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 5.30% 7.06% 10.11% 11.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 18.21% 14.81% 16.06% 15.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -207.11% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 76.49% 78.13% 73.82% 73.15% 100.00% 307.11% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.72 0.72 -2.23 -0.54 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -3.36 -3.04 8.54 2.01 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.56 0.49 -1.37 -0.31 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.96 1.78 -2.58 -0.73 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -4.51 -7.46 9.92 2.73 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.75 1.20 -1.59 -0.42 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.08 -0.33 -1.17 -2.19 -2.92 -4.57 -2.99 -1.38 -1.18 -1.19
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -599.64% 0.00% 0.00% 0.00% -197.72%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 6.73 5.91 5.22 4.18 4.51 1.33 3.03 4.78 10.70 9.43
Quick Ratio		 6.46 5.76 5.00 4.00 4.24 1.21 2.88 4.57 10.47 9.29
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -97 -74 -24 -17 -26 180 186 180 187 -19
Operating Cash Flow to CapEx		 749.23% -17,953.03% -6,742.31% -82,458.33% 0.00% -36,384.38% -2,644.02% -910.27% 220.86% -993.19%
Free Cash Flow to Firm to Interest Expense		 -121.47 -91.64 -29.66 -22.64 -20.06 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 5.43 -14.68 -10.85 -13.16 -7.24 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 4.70 -14.76 -11.01 -13.17 -7.24 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.72 0.68 0.55 0.30 0.24 0.11 0.11 0.22 0.17 0.11
Accounts Receivable Turnover		 17.39 11.26 11.82 3.31 5.84 3.33 5.86 2.89 9.86 11.54
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 52.61 44.89 30.33 17.95 12.97 10.60 10.03 11.68 7.58 6.47
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 20.99 32.41 30.87 110.11 62.48 109.68 62.31 126.24 37.03 31.62
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 20.99 32.41 30.87 110.11 62.48 109.68 62.31 126.24 37.03 31.62
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -39 -18 -28 -26 -23 -224 -224 -192 -222 -223
Invested Capital Turnover		 -1.42 -2.19 -2.45 -1.74 -1.12 -0.22 -0.21 -0.50 -0.39 -0.17
Increase / (Decrease) in Invested Capital		 96 65 11 3.98 16 -206 -195 -166 -199 0.54
Enterprise Value (EV)		 128 63 112 82 81 325 -0.15 391 123 241
Market Capitalization		 250 173 213 172 163 107 105 481 345 455
Book Value per Share		 $0.56 $0.61 $0.49 $0.43 $0.39 ($2.84) ($0.72) ($5.70) $0.04 ($0.27)
Tangible Book Value per Share		 $0.56 $0.61 $0.49 $0.43 $0.39 ($4.12) ($1.95) ($16.87) ($9.26) ($8.09)
Total Capital		 111 120 101 89 60 -143 -117 -101 0.75 -6.80
Total Debt		 26 26 26 24 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 20 18 16 14 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -122 -110 -101 -90 -82 -79 -105 -89 -221 -215
Capital Expenditures (CapEx)		 0.58 0.07 0.13 0.01 0.00 0.06 0.60 1.59 6.20 0.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.61 -3.07 -3.85 -8.43 -9.67 -54 -29 11 -11 -19
Debt-free Net Working Capital (DFNWC)		 142 132 122 104 70 23 74 99 208 194
Net Working Capital (NWC)		 136 123 112 93 70 23 74 99 208 194
Net Nonoperating Expense (NNE)		 6.77 -14 8.80 -1.66 -0.14 152 47 -0.08 12 -8.46
Net Nonoperating Obligations (NNO)		 -124 -112 -103 -91 -83 -80 -107 -91 -223 -216
Total Depreciation and Amortization (D&A)		 0.56 -0.94 0.13 0.18 0.19 0.27 0.18 0.20 0.29 0.49
Debt-free, Cash-free Net Working Capital to Revenue		 -3.72% -2.77% -4.65% -17.32% -28.01% -209.16% -111.80% 21.15% -23.92% -48.72%
Debt-free Net Working Capital to Revenue		 114.45% 118.74% 147.59% 212.75% 202.50% 86.60% 287.40% 182.37% 433.33% 497.65%
Net Working Capital to Revenue		 109.71% 111.09% 135.24% 191.73% 202.50% 86.60% 287.40% 182.37% 433.33% 497.65%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.50) $1.20 ($4.20) ($2.10) ($1.80) ($1,030.80) ($10.50) $0.58 ($1.13) ($0.35)
Adjusted Weighted Average Basic Shares Outstanding		 5.10M 4.83M 5.11M 5.11M 5.16M 172.34K 5.41M 16.72M 21.47M 17.28M
Adjusted Diluted Earnings per Share		 ($1.50) $1.20 ($4.20) ($2.10) ($1.80) ($1,030.80) ($10.50) $0.54 ($1.13) ($0.35)
Adjusted Weighted Average Diluted Shares Outstanding		 5.10M 4.86M 5.11M 5.11M 5.16M 172.34K 5.41M 17.79M 21.47M 17.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $1.20 $0.00 $0.00 $0.00 ($1,030.80) $0.00 $0.00 $0.00 ($0.35)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.10M 5.11M 5.11M 5.11M 5.17M 5.40M 17.80M 21.38M 25.41M 25.91M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.12 -5.95 -13 -13 -9.15 -25 -9.34 9.63 -12 -19
Normalized NOPAT Margin		 -5.40% -35.41% -216.68% -248.55% -139.60% -307.67% -159.99% 28.79% -3,178.94% 0.00%
Pre Tax Income Margin		 -39.66% 6.62% -300.42% -342.41% -199.08% -2,296.83% -981.71% 44.71% -6,313.44% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -10.13 0.56 -22.73 -24.75 -10.27 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -1.40 -10.53 -15.92 -17.35 -7.18 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -10.85 0.47 -22.89 -24.77 -10.27 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -2.12 -10.61 -16.09 -17.37 -7.18 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.09%

Financials Breakdown Chart

Key Financial Trends

Cartesian Therapeutics (NASDAQ: RNAC) showed a dramatic improvement in its revenue and cash position during 2024 compared with 2023, but the company remains highly dependent on outside capital and is still losing money. The latest quarter also included a major swing in cash flow and a significant dilution event, which are important considerations for retail investors.

  • Revenue improved sharply in 2024: Q2 2024 revenue was $33.4 million and Q3 2024 revenue was $387,000, while Q4 2024 revenue was a loss-like negative reported amount in the dataset; more broadly, the year included a large revenue event in Q2 that was far above prior-year quarterly levels.
  • Cash balance remained very strong entering Q4 2024: cash and equivalents were $219.2 million at the end of Q3 2024, up from $87.2 million at the end of Q2 2024 and $103.4 million at the end of Q1 2024.
  • Operating cash flow turned positive in Q3 2024: the company generated $13.7 million in operating cash flow in Q3 2024, a notable improvement from negative $14.4 million in Q2 2024 and negative $15.9 million in Q1 2024.
  • 2024 Q2 produced operating profit: Cartesian reported operating income of $13.8 million in Q2 2024, suggesting the business can be profitable in a strong quarter.
  • Interest and investment income helped results: the company reported meaningful interest income in 2024, including $2.45 million in Q4 and $2.57 million in Q3, which helped offset operating losses.
  • R&D spending stayed high: research and development expense remained elevated at $11.3 million in Q4 2024, $11.4 million in Q3 2024, and $12.7 million in Q2 2024, indicating continued heavy investment in the pipeline.
  • Balance sheet equity is still unstable: total common equity was only $752,000 at the end of Q3 2024, after being negative $101.5 million at the end of Q2 2024 and negative $116.8 million at the end of Q1 2024.
  • The company carries substantial noncurrent liabilities: other noncurrent operating liabilities were $417.3 million at Q3 2024, up from $407.2 million at Q2 2024 and $389.5 million at Q1 2024.
  • Q4 2024 returned to a net loss: consolidated net loss was $10.3 million, compared with net income of $13.8 million in Q2 2024.
  • Cash declined in Q4 2024: net change in cash and equivalents was negative $6.6 million in the quarter, showing continued cash burn despite the prior large cash balance.
  • Shares outstanding increased materially in 2024: weighted average basic shares rose from 5.4 million in Q1 2024 to 21.5 million in Q3 2024, while Q4 2024 basic shares were 17.3 million, indicating meaningful dilution.
  • Profitability remains inconsistent: 2023 was marked by large losses, including a Q4 2023 net loss of $177.7 million, highlighting how volatile results can be for this company.

Bottom line: Cartesian Therapeutics ended 2024 with a much better cash position than it had a year earlier, and it demonstrated that it can post profitable quarters. However, the business is still volatile, unprofitable on a trailing basis, and highly reliant on financing and dilution. Investors will likely focus on whether the company can convert its 2024 operating progress into sustained revenue and margin improvement.

06/15/26 02:43 AM ETAI Generated. May Contain Errors.

Cartesian Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cartesian Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Cartesian Therapeutics' net income appears to be on an upward trend, with a most recent value of -$77.42 million in 2024, falling from $35.38 million in 2022. The previous period was -$219.71 million in 2023. See Cartesian Therapeutics' forecast for analyst expectations on what's next for the company.

Cartesian Therapeutics' total operating income in 2024 was -$43.90 million, based on the following breakdown:
  • Total Gross Profit: $38.91 million
  • Total Operating Expenses: $82.81 million

Over the last 2 years, Cartesian Therapeutics' total revenue changed from $110.78 million in 2022 to $38.91 million in 2024, a change of -64.9%.

Cartesian Therapeutics' total liabilities were at $441.83 million at the end of 2024, a 0.6% decrease from 2023, and a 513.2% increase since 2022.

In the past 2 years, Cartesian Therapeutics' cash and equivalents has ranged from $76.91 million in 2023 to $212.61 million in 2024, and is currently $212.61 million as of their latest financial filing in 2024.

Over the last 2 years, Cartesian Therapeutics' book value per share changed from 0.61 in 2022 to -0.27 in 2024, a change of -143.6%.


Related Companies

Financial statements for NASDAQ:RNAC last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel